CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced positive results from an investigational new drug-enabling study of the Company’s second-generation telomere-targeting agents derived from lipid-modified THIO molecules.

芝加哥-（商业线）-MAIA Biotechnology，Inc。（纽约州美国：MAIA）是一家开发针对癌症的端粒靶向免疫疗法的临床阶段公司，今天宣布该公司第二代研究性新药启用研究的积极成果端粒靶向剂衍生自脂质修饰的硫代分子。

MAIA’s second-generation telomere-targeting molecule program seeks to discover new compounds with improved specificity towards cancer cells relative to normal cells, potentially increased anticancer activity, and stronger chemistry manufacturing control characteristics..

MAIA的第二代端粒靶向分子计划旨在发现相对于正常细胞对癌细胞具有更高特异性的新化合物，可能增加抗癌活性，并增强化学制造控制特性。。

“In this study we demonstrated broad-spectrum therapeutically-attractive opportunities for specific telomeric stress-inducing treatments. The results demonstrate an increase in innate sensing and adaptive antitumor immunity via the self-produced chemical modification of cancer cell telomeres by THIO,” said MAIA’s Chief Scientific Officer Sergei Gryaznov, Ph.D..

MAIA的首席科学官Sergei Gryaznov博士说：“在这项研究中，我们展示了广谱治疗特异性端粒应激诱导治疗的有吸引力的机会。结果表明，通过THIO对癌细胞端粒的自我产生的化学修饰，先天感知和适应性抗肿瘤免疫力增加。。

The new THIO prodrugs are lipid conjugated compounds derived from THIO. The prodrugs are pharmacologically inactive compounds that, after intake, are metabolized into a pharmacologically active drug. In vitro, these compounds were able to induce telomeric DNA damage responses that were similar or more profound than those for THIO, as assessed by quantitative Telomere Damage Induced Foci assays (TIF formation).

新的硫代前药是衍生自硫代的脂质缀合的化合物。前药是药理学上无活性的化合物，其在摄入后被代谢成药理活性药物。在体外，如通过定量端粒损伤诱导的病灶测定（TIF形成）所评估的，这些化合物能够诱导与THIO相似或更深刻的端粒DNA损伤应答。

Efficient formation of micronuclei structures was also observed. Initial in vivo evaluation of the anticancer activity, conducted in human xenografts and murine syngeneic models of colorectal cancer, demonstrated potent anticancer activity at relatively low dose levels for one of the lead lipid conjugates..

还观察到微核结构的有效形成。在结肠直肠癌的人异种移植物和鼠同系模型中进行的抗癌活性的初始体内评估证明，对于一种先导脂质缀合物，在相对低的剂量水平下具有有效的抗癌活性。。

“Our findings from this study demonstrate the significance of telomeric DNA structural and functional integrity for cancer cell survival. The high potency of these THIO-like agents warrants further in vivo in-depth investigation as a potential next generation of telomerase-mediated telomere-targeting compounds,” said Vlad Vitoc, M.D., MAIA’s Chief Executive Officer..

“我们从这项研究中得到的结果证明了端粒DNA结构和功能完整性对于癌细胞存活的重要性，这些硫类药物的高效力值得进一步深入研究，作为潜在的下一代端粒酶介导的端粒靶向化合物，”MAIA首席执行官Vlad Vitoc博士说。。

The findings were presented by Dr. Gryaznov at the International Biochemistry Congress 2023, organized by the Turkish Biochemical Society and held in Turkey. The findings are detailed in the abstract available in the event website under Speakers, Sergei M. Gryaznov and Lecture Abstract sections.

Gryaznov博士在2023年国际生物化学大会上介绍了这些发现，该大会由土耳其生物化学学会组织并在土耳其举行。调查结果详见活动网站上的演讲人Sergei M.Gryaznov和讲座摘要部分的摘要。

The telomere-centric action of MAIA’s lead candidate THIO is being evaluated in Phase 2 clinical trials (THIO-101) in non-small-cell lung carcinoma (NSCLC) patients.

MAIA的主要候选THIO的端粒中心作用正在非小细胞肺癌（NSCLC）患者的2期临床试验（THIO-101）中进行评估。

About THIO

关于THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.

THIO（6-硫代-dG或6-硫代-2'-脱氧鸟苷）是目前临床开发中用于评估其在非小细胞肺癌（NSCLC）中的活性的一流的研究性端粒靶向剂。端粒与端粒酶一起在癌细胞的存活及其对当前疗法的抗性中起基础作用。

The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses.

修饰的核苷酸6-硫代-2'-脱氧鸟苷（thio）诱导端粒酶依赖性端粒DNA修饰，DNA损伤应答和选择性癌细胞死亡。硫代损伤的端粒片段积聚在胞质微核中并激活先天性（cGAS/STING）和适应性（T细胞）免疫应答。

The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors..

THIO随后PD-（L）1抑制剂的顺序治疗通过诱导癌症类型特异性免疫记忆导致晚期体内癌症模型中的深度和持续的肿瘤消退。THIO目前被开发为NSCLC的第二或更晚的治疗方案，用于已经超出现有检查点抑制剂标准治疗方案的患者。。

About MAIA Biotechnology, Inc.

关于MAIA生物技术公司。

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

MAIA是一家靶向治疗免疫肿瘤公司，致力于开发和商业化潜在的一流药物，具有旨在有意义地改善和延长癌症患者生活的新型作用机制。我们的主要计划是THIO，这是一种潜在的一流的癌症端粒靶向剂，用于临床开发，用于治疗端粒酶阳性癌细胞的NSCLC患者。

For more information, please visit www.maiabiotech.com..

欲了解更多信息，请访问www.maiabiotech.com。。

Forward Looking Statements

前瞻性声明

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements.

MAIA警告说，除了本新闻稿中包含的历史事实陈述外，所有陈述都是前瞻性陈述。前瞻性陈述受到已知和未知的风险，不确定性以及其他可能导致我们或我们行业的实际结果，水平或活动，绩效或成就与此类陈述预期实质性不同的因素的影响。

The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking.

使用诸如“可能”，“可能”，“将会”，“应该”，“可以”，“期望”，“计划”，“预期”，“相信”，“估计”，“项目”，“意图”，“未来”，“潜力”或“继续”，以及其他类似的表达方式旨在识别前瞻性陈述。但是，缺少这些词语并不意味着陈述不是前瞻性的。

For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking.

例如，我们就（i）我们的临床前和临床研究以及我们的研究和开发计划的启动，时间，成本，进展和结果，（ii）我们将候选产品推进并成功完成临床研究的能力，（iii）监管文件和批准的时间或可能性，（iv）我们的发展能力，制造和商业化我们的候选产品并改善制造工艺，（v）我们候选产品的市场接受率和程度，（vi）我们候选产品的市场规模和增长潜力以及我们为这些市场服务的能力，（vii）我们对我们获得和维护产品候选人知识产权保护能力的期望是期待的。

All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expr.

所有前瞻性陈述均基于我们管理层目前的估计，假设和期望，尽管我们认为这是合理的，但本质上是不确定的。任何前瞻性声明expr。